Early Stopping Rules in Clinical Trials Based on Sequential Monitoring of Serious Adverse Events

A. Kramar and C. Bascoul-Mollevi
Additional contact information
A. Kramar: Unité de Biostatistique, CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France, andrew.kramar@valdorel.fnclcc.fr
C. Bascoul-Mollevi: Unité de Biostatistique, CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France

Medical Decision Making, 2009, vol. 29, issue 3, 343-350

Abstract: Several multistage or group sequential statistical methods have been developed for defining stopping rules in terms of efficacy in phase II and III clinical trials, but they rely on interim analyses after the inclusion of a fixed number of patients. These methods, however, need to be adapted for the evaluation of serious adverse events (SAEs), which can occur relatively early in the trial. A high frequency of their occurrence may require the trial to close early. The methods developed here define stopping rules after the occurrence of each SAE by comparing the number of patients included to the number of patients satisfying maximum SAE criteria. The nominal type I error, power, and average sample number (ASN) under specific hypotheses are obtained through simulations. Data from a clinical trial are presented as an example.

Keywords: early stopping rules; serious adverse event; clinical trials. (search for similar items in EconPapers)
Date: 2009
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X08327332 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:29:y:2009:i:3:p:343-350

DOI: 10.1177/0272989X08327332

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().